Zhuajin Bi

Zhengzhou, 450000, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

HMGB1-mediated endoplasmic reticulum stress in monocyte-derived dendritic cells regulates CD4+ T cell immune responses in myasthenia gravis.

HMGB1-mediated endoplasmic reticulum stress in monocyte-derived dendritic cells regulates CD4+ T cell immune responses in myasthenia gravis.

Journal: Journal of neuroinflammation

Published: March 19, 2026

Efgartigimod for Guillain-Barré syndrome: a retrospective analysis of efficacy and safety.

Efgartigimod for Guillain-Barré syndrome: a retrospective analysis of efficacy and safety.

Journal: Therapeutic advances in neurological disorders

Published: August 01, 2025

The pathogenesis of immune-mediated necrotizing myopathy: Progress and therapeutic implications.

The pathogenesis of immune-mediated necrotizing myopathy: Progress and therapeutic implications.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 12, 2025

Efgartigimod as a Fast-Acting Add-On Therapy in Antibody-Mediated Autoimmune Encephalitis.

Efgartigimod as a Fast-Acting Add-On Therapy in Antibody-Mediated Autoimmune Encephalitis.

Journal: European journal of neurology

Published: March 08, 2025

Resolution of anti-GAD-associated autoimmune encephalitis in patients treated with efgartigimod.

Resolution of anti-GAD-associated autoimmune encephalitis in patients treated with efgartigimod.

Journal: Frontiers in neurology

Published: March 04, 2025

Comparison of outcomes and postoperative immunotherapy between patients with non-thymomatous and thymomatous myasthenia gravis following thymectomy.

Comparison of outcomes and postoperative immunotherapy between patients with non-thymomatous and thymomatous myasthenia gravis following thymectomy.

Journal: Therapeutic advances in neurological disorders

Published: December 10, 2024

Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study.

Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: July 22, 2024

The JAK1/3 Inhibitor Tofacitinib Regulates Th Cell Profiles and Humoral Immune Responses in Myasthenia Gravis.

The JAK1/3 Inhibitor Tofacitinib Regulates Th Cell Profiles and Humoral Immune Responses in Myasthenia Gravis.

Journal: Muscle & nerve

Published: July 20, 2024

Predictive Factors for Poor Outcomes Associated with COVID-19 in a Retrospective Cohort of Myasthenia Gravis Patients.

Predictive Factors for Poor Outcomes Associated with COVID-19 in a Retrospective Cohort of Myasthenia Gravis Patients.

Journal: Journal of inflammation research

Published: April 26, 2024

Exhausted signature and regulatory network of NK cells in myasthenia gravis.

Exhausted signature and regulatory network of NK cells in myasthenia gravis.

Journal: Frontiers in immunology

Published: March 08, 2024

Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.

Clinical Features, Treatment, and Prognostic Factors of Childhood-Onset Myasthenia Gravis in a Large Chinese Cohort.

Journal: Pediatric neurology

Published: March 27, 2023

Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.

Clinical and immune-related factors associated with exacerbation in adults with well-controlled generalized myasthenia gravis.

Journal: Frontiers in immunology

Published: March 01, 2023

Showing 1-12 of 27

Last Updated: 09/26/2026